Form 4: Pfizer Executive Vice President Lidia Fonseca Reports Acquisition of Stock Appreciation Rights
SEC Form 4 Filing
Executive Vice President Lidia Fonseca reports acquisition of Pfizer stock appreciation rights.
Summary
- Lidia Fonseca, an Executive Vice President at Pfizer Inc., filed a Form 4 on March 6, 2025, reporting a transaction.
- The transaction involved the acquisition of 156,992 stock appreciation rights (SARs) at a price of $25.75 on March 4, 2025.
- These SARs are subject to vesting requirements and will be settled in shares of Pfizer common stock on March 4, 2030, the fifth anniversary of the grant date.
- Following the reported transaction, Fonseca directly owns 156,992 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, indicating a neutral sentiment.
Future Outlook
The stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date (March 4, 2030).
Industry Context
Form 4 filings are standard practice for corporate insiders to report transactions in their company's securities, providing transparency to the market.
Key Dates
| Date | Description |
|---|---|
| 03/04/2025 | Date of earliest transaction: Acquisition of stock appreciation rights. |
| 03/04/2025 | Transaction Date: Acquisition of stock appreciation rights. |
| 03/04/2030 | Expiration Date: Stock appreciation rights will be settled in shares of Pfizer common stock. |
| 03/06/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.